114772-36-0

Basic information

• Product Name: TERT-BUTYL 4'-METHYLBIPHENYL-2-CARBOXYLATE
• Synonyms: 4'-METHYL-BIPHENYL-2-CARBOXYLIC ACID TERT-BUTYL ESTER;4'-METHYLBIPHENYL-2-TERTIARY BUTYL FORMATE;TERT-BUTYL 4'-METHYLBIPHENYL-2-CARBOXYLATE;TERT-BUTYL 4'-METHYL-[1,1'-BIPHENYL]-2-CARBOXYLATE;2-(p-Tolyl)-benzoic acid tert-butyl ester;tert-Butyl 4'-methylbiphenyl-2-carboxylate;[1,1'-Biphenyl]-2-carboxylicacid, 4'-Methyl-, 1,1-diMethylethyl;[1,1'-Biphenyl]-2-carboxylic acid, 4'-methyl-, 1,1-dimethylethyl ester
• CAS NO: 114772-36-0
• Molecular Formula: C₁₈H₂₀O₂
• Molecular Weight: 268.35
• Product Categories: Biphenyl & Diphenyl ether
• Mol File: 114772-36-0.mol

Chemical Properties

• Boiling Point: 388.892 °C at 760 mmHg
• Flash Point: 162.608 °C
• Appearance: /
• Density: 1.038 g/cm³
• CAS DataBase Reference: TERT-BUTYL 4'-METHYLBIPHENYL-2-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 4'-METHYLBIPHENYL-2-CARBOXYLATE(114772-36-0)
• EPA Substance Registry System: TERT-BUTYL 4'-METHYLBIPHENYL-2-CARBOXYLATE(114772-36-0)

Safety Data

• Hazardous Substances Data: 114772-36-0(Hazardous Substances Data)

Usage

Uses

Used in Cosmetic and Personal Care Industry:
TERT-BUTYL 4'-METHYLBIPHENYL-2-CARBOXYLATE is used as a fragrance and flavoring agent for its appealing scent, enhancing the sensory experience of perfumes, lotions, and other consumer products.
Used in Pharmaceutical Manufacturing:
In the pharmaceutical industry, TERT-BUTYL 4'-METHYLBIPHENYL-2-CARBOXYLATE is used as a component in the production of medicines, contributing to the development of various medicinal formulations.
Used as a Flavor Enhancer in Food Industry:
TERT-BUTYL 4'-METHYLBIPHENYL-2-CARBOXYLATE is used as a flavor enhancer in food products to improve taste and provide a more enjoyable culinary experience.
It is crucial to handle TERT-BUTYL 4'-METHYLBIPHENYL-2-CARBOXYLATE with care and adhere to safety guidelines to minimize any potential health risks associated with its use.

Upstream product

• 55666-42-7 tert-butyl 2-bromobenzoate 
• 5720-05-8 4-methylphenylboronic acid 
• 865-47-4 potassium tert-butylate 
• 114772-35-9 4'-methylbiphenyl-2-carboxylic acid chloride 
• 7148-03-0 o-tolylbenzoic acid 
• 115-11-7 isobutene 
• 106-38-7 para-bromotoluene 
• 110349-26-3 tert-butyl 2-iodobenzoate 
• 88-65-3 2-bromobenzoic-acid 
• 114772-34-8 methyl 4'-methylbiphenyl-2-carboxylate 
• 57598-33-1 2-(2-methoxyphenyl)-4,4-dimethyl-2-oxazoline 
• 74201-13-1 N-(2-hydroxy-1,1-dimethyl)-2-methoxybenzamide 
• 84392-32-5 4,4-dimethyl-2-(4'-methyl-biphenyl-2-yl)-4,5-dihydrooxazole 
• 579-75-9 2-Methoxybenzoic acid 

Downstream Products

• 114772-40-6 4'-bromomethyl-biphenyl-2-carboxylic acid tert-butyl ester 
• 133690-73-0 4'-(Aminomethyl)[1,1'-biphenyl]-2-carboxylic acid,1,1-dimethylethyl ester 
• 139476-15-6 4'-(1,3-Dibutyl-5-oxo-1,5-dihydro-[1,2,4]triazol-4-ylmethyl)-biphenyl-2-carboxylic acid tert-butyl ester 
• 114772-46-2 1-<<2'-(tert-butoxycarbonyl)biphenyl-4-yl>methyl>-2-butyl-5-(hydroxymethyl)-4-iodoimidazole 
• 124750-54-5 1-<<2'-(tert-butoxycarbonyl)biphenyl-4-yl>methyl>-4-methyl-2-propylimidazole-5-carboxaldehyde 
• 124750-55-6 1-<<2'-(tert-butoxycarbonyl)biphenyl-4-yl>methyl>-5-(hydroxymethyl)-4-methyl-2-propylimidazole 
• 114798-95-7 2-butyl-1-<(2'-carboxybiphenyl-4-yl)methyl>-5-(hydroxymethyl)-4-nitroimidazole 
• 114798-96-8 2-butyl-1-<(2'-carboxylbiphenyl-4-yl)methyl>-5-(hydroxymethyl)-4-(trifluoromethyl)imidazole 
• 124750-36-3 1-<<2'-(tert-butoxycarbonyl)biphenyl-4-yl>methyl>-2-butyl-5-(hydroxymethyl)-4-nitroimidazole 
• 114772-62-2 1-<<2'-(tert-butoxycarbonyl)biphenyl-4-yl>methyl>-2-butyl-4-iodo-5-<<(2-methoxyethoxy)methoxy>methyl>imidazole 
• 114772-63-3 1-<<2'-(tert-butoxycarbonyl)biphenyl-4-yl>methyl>-2-butyl-5-<<(2-methoxyethoxy)methoxy>methyl>-4-(trifluoromethyl)imidazole 
• 124750-09-0 1-<(2'-carboxylbiphenyl-4-yl)methyl>-5-(hydroxymethyl)-4-methyl-2-propylimidazole hydrochloride 
• 901768-33-0 4'-dibromomethyl-biphenyl-2-carboxylic acid tert-butyl ester 
• 1415256-24-4 (S)-tert-butyl 4'-((5-((1-(4-(tert-butyl)phenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1'-biphenyl]-2-carboxylate 

Relevant articles and documents

Discovery of TD-0212, an Orally Active Dual Pharmacology AT1 Antagonist and Neprilysin Inhibitor (ARNI)

Dual inhibition of angiotensin-converting enzyme (ACE) and neprilysin (NEP) by drugs such as omapatrilat produces superior antihypertensive efficacy relative to ACE inhibitors but is associated with a higher risk of life-threatening angioedema due to bradykinin elevations. We hypothesized that dual AT1 (angiotensin II type 1 receptor) blockade and NEP inhibition with a single molecule would produce similar antihypertensive efficacy to omapatrilat without the risk of angioedema since ACE (the rate limiting enzyme in bradykinin metabolism) would remain uninhibited. Merging the structures of losartan (an AT1 antagonist) and thiorphan (a NEP inhibitor) led to the discovery of a novel series of orally active, dual AT1 antagonist/NEP inhibitors (ARNIs) exemplified by compound 35 (TD-0212). In models of renin-dependent and -independent hypertension, 35 produced blood pressure reductions similar to omapatrilat and combinations of AT1 receptor antagonists and NEP inhibitors. Upper airway angioedema risk was assessed in a rat tracheal plasma extravasation (TPE) model. Unlike omapatrilat, 35 did not increase TPE at antihypertensive doses. Compound 35 therefore provides the enhanced activity of dual AT1/NEP inhibition with a potentially lower risk of angioedema relative to dual ACE/NEP inhibition.

Copper-catalyzed cross-coupling of aryl-, primary alkyl-, and secondary alkylboranes with heteroaryl bromides

A method for the Cu-catalyzed cross-coupling of both aryl and alkylboranes with aryl bromides is described. The method employs an inexpensive Cu-catalyst and functions for a variety of heterocyclic as well as electron deficient aryl bromides. In addition, aryl iodides of varying substitution patterns and electronic properties work well.

PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS

The invention provides methods of treatment of a progressive bone disease, such as osteoporosis, Paget's Disease, multiple myeloma, or hyperparathyroidism, comprising administration of an effective amount of a non-agonist PPARG modulator to a patient afflicted with the disease.

N-ARYLYLMETHYLINDAZOLE MODULATORS OF PPARG

The invention provides molecular entities that bind with high affinity to PPARG (PPARy), inhibit cdJk5-mediated phosphorylation of PP ARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes or obesity. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.

N-BIPHENYLMETHYLINDOLE MODULATORS OF PPARG

The invention provides molecular entities that bind with high affinity to PPARG (PPAR3), inhibit kinase-mediated, e.g., cdk5-mediated, phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes, insulin resistance, impaired glucose tolerance, pre-diabetes, hyperglycemia, hyperinsulinemia, obesity, or inflammation. In methods of treatment of these conditions using a compound of the invention, the compound can avoid producing side effects of significant weight gain, edema, impairment of bone growth or formation, or cardiac hypertrophy, or any combination thereof, in the patient receiving the compound. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.

The discovery of new potent non-peptide Angiotensin II AT1 receptor blockers: A concise synthesis, molecular docking studies and biological evaluation of N-substituted 5-butylimidazole derivatives

A convenient and facile synthesis, in silico docking studies and in vitro biological evaluation of N-substituted 5-butylimidazole derivatives as potent Angiotensin II (ANG II) receptor type 1 (AT1) blockers (ARBs) has been reported in the current study. Our efforts have been directed towards the development of an efficient synthetic route allowing the facile introduction of substituents on the imidazole ring. In particular, a series of imidazole based compounds bearing the biphenyl moiety at the N - 1 position, a halogen atom at the C-4 and polar substituents such as hydroxymethyl, aldo or carboxy group at the C-2 position were designed and synthesized. These compounds were evaluated for binding to human AT1 receptor and for ANG II antagonism in vitro on isolated rat uterus. Among them, 5-butyl-1-[[2′-(2H-tetrazol-5-yl)biphenyl-4-yl] methyl]imidazole-2-carboxylic acid (30) exhibited higher binding affinity compared to the other analogues tested (-log IC50 = 8.46). The latter analogue was also found to be the most active in the rat uterotonic test (pA2 = 7.83). Importantly, the binding affinity was higher to that of losartan (-log IC50 = 8.25) indicating the importance of carboxy group at the C-2 position. Experimental findings are in good agreement with docking studies, which were undertaken in order to investigate ligand/AT1 receptor interactions.

DUAL-ACTING ANTIHYPERTENSIVE AGENTS

In one aspect, the invention relates to compounds having the formula: wherein: Ar, r, Z, X, R3, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

DUAL-ACTING ANTIHYPERTENSIVE AGENTS

The invention relates to compounds having the formula: (I) wherein: Ar, r, R3, Z, X, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

Dual-acting antihypertensive agents

The invention is directed to compounds having the formula: wherein: Ar, r, Y, Z, Q, W, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

Dual-acting antihypertensive agents

The invention is directed to compounds of formula I: wherein Ar, r, R3, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula I have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and a process and intermediates for preparing such compounds.